← Human Trials & Peer-Reviewed Studies

The Effect of Exercise on Spexin and Follistatin in Elderly Individuals.

Plain-language guide to PMID 39895162 (2025): multicenter randomized controlled trial of Follistatin-344 in 66 subjects.

Key Facts

PMID
39895162
Journal
Journal of cachexia, sarcopenia and muscle
Year
2025
Study type
Randomized Controlled Trial
Authors
Ayaz EY et al. (8 authors)
DOI
10.1002/jcsm.13692
Registered trial
NCT05251597

What This Study Did, in Plain Language

What Was Tested

Researchers studied Follistatin-344 in this randomized controlled trial publication.

The aim of the study investigate the effects of 12 weeks of aerobic and resistance exercise training on spexin and follistatin and their relationship with each other.

Why It Was Studied

In adipose tissue-muscle crosstalk mechanisms, the interaction of adipokines and myokines is known to be critical for maintaining the body's metabolic balance in age-related metabolic disorders.

Who Took Part

The abstract describes 66 subjects taking part.

By PubMed's age tags, the people studied were older adults and people over 80, both men and women.

This study was a multicentre, randomized controlled study conducted at two assisted living facilities with participants aged ≥ 65.

Among the 66 subjects, 33 were allocated to the exercise group (E) and 33 to the control group (C).

How the Study Was Run

In design terms this was a randomized and multicenter study.

The subjects were allocated by chance, so the Follistatin-344 group and the comparison group should start out alike.

More than one site took part, so the subjects came from several places.

Participants in the intervention groups performed exercise assignments two extra days a week, tailored to their specific circumstances and supervised by the institution's physiotherapists.

What Was Measured

The subject headings attached to it are Follistatin, Exercise, Peptide Hormones and Resistance Training.

Author keywords: elderly individuals, metabolic syndrome and spexin.

What This Means in Plain Language

The paper is a randomized and multicenter study of Follistatin-344 in 66 subjects.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Journal of cachexia, sarcopenia and muscle), a journal based in Germany.

More context: the Follistatin-344 compound page, all human trials.

Our Notes on the Compound

Follistatin-344: A myostatin- and activin-binding protein studied in gene-therapy trials for muscular dystrophy; black-market vials have been found mislabeled.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.